The latest generation MDM2 inhibitor RG7388 has demonstrated selective and potent p53 to MDM2 inhibition with improved bioavailability.24 Herein, we utilize RG7388 and examine the effect of this novel inhibitor in neuroblastoma both in vitro and in vivo. This evidence concerns the gene TP53 and neuroblastoma.